Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2358 PWToday Stories

Sebia signs agreement with Janssen Biotech to develop a multiple myeloma IVD test

31 Jan 17

Sebia, a world leader in multiple myeloma (MM) diagnostics and monitoring, announces today that it has entered into an agreement with Janssen Biotech, Inc. (Horsham, PA, USA), for the development of an In Vitro diagnostic (IVD) test that mitigates the potential interference in visualization of M-proteins in immunofixation electrophoresis caused by DARZALEX® (daratumumab). DARZALEX® is a human monoclonal antibody targeting CD38 that has been shown to provide superior clinical benefit as monotherapy in heavily pre-treated multiple myeloma patients and when combined with standard of care regimens for the treatment of MM in patients with the earlier disease (e.g. >1 prior line of therapy). This agreement is the first collaboration of its kind for Sebia. The financial details were not disclosed.
The agreement covers the development of the Hydrashift 2/4 daratumumab IVD reagent kit for use with Sebia’s proprietary immunofixation (IF) test, Hydragel. Janssen granted Sebia development rights, allowing Sebia to be the worldwide supplier, able to provide the IVD solution to remove the daratumumab interference from the IF test. Sebia’s broad market coverage guarantees that patients using DARZALEX® in many countries throughout the world will have access to testing.
It is well known that the newer treatments for multiple myeloma that use humanized monoclonal antibodies (mAbs) can interfere with the patient’s native antibodies in immunofixation tests. This can mislead the pathologist in interpreting the patient’s response to treatment. Immunofixation is one of the tests referenced in the IMWG (International Myeloma Working Group) guidelines to establish the diagnosis of complete response in a patient with multiple myeloma.
This IVD test is specific for patients treated by DARZALEX®, to be used only on Sebia’s FDA cleared and CE marked Hydrasys 2 agarose gel platform. It cannot be used for other patient samples with any other interfering monoclonal antibodies or any other immunofixation test.
“We are excited about partnering with Janssen and further expanding our reach in the international diagnostic market,” said Benoit Adelus, CEO at Sebia. “This is great news for patients around the world who will now have access to a reliable IVD test. Hydrashift 2/4 daratumumab is in line with our strategy of developing innovative and advanced products for patient care.”

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.